TriCalm® hydrogel is significantly superior to 2% diphenhydramine and 1% hydrocortisone in reducing the peak intensity, duration, and overall magnitude of cowhage-induced itch

Background: Itch is one of the most frequent skin complaints and its treatment is challenging. From a neurophysiological perspective, two distinct peripheral and spinothalamic pathways have been described for itch transmission: a histaminergic pathway and a nonhistaminergic pathway mediated by protease-activated receptors (PAR)2 and 4. The nonhistaminergic itch pathway can be activated exogenously by spicules of cowhage, a tropical plant that releases a cysteine protease named mucunain that binds to and activates PAR2 and PAR4.

Purpose: This study was conducted to assess the antipruritic effect of a novel over-the-counter (OTC) steroid-free topical hydrogel formulation, TriCalm®, in reducing itch intensity and duration, when itch was induced with cowhage, and compared it with two other commonly used OTC anti-itch drugs.

Study participants and methods: This double-blinded, vehicle-controlled, randomized, crossover study recorded itch intensity and duration in 48 healthy subjects before and after skin treatment with TriCalm hydrogel, 2% diphenhydramine, 1% hydrocortisone, and hydrogel vehicle, used as a vehicle control.

Results: TriCalm hydrogel significantly reduced the peak intensity and duration of cowhage-induced itch when compared to the control itch curve, and was significantly superior to the two other OTC antipruritic agents and its own vehicle in antipruritic effect. TriCalm hydrogel was eight times more effective than 1% hydrocortisone and almost six times more effective than 2% diphenhydramine in antipruritic action, as evaluated by the reduction of area under the curve.

Conclusion: TriCalm hydrogel has a robust antipruritic effect against nonhistaminergic pruritus induced via the PAR2 pathway, and therefore it could represent a promising treatment option for itch.

Keywords: antipruritic treatment, nonhistaminergic pruritus, head-to-head comparison

Introduction
Itch has been reported as the most frequent complaint in the dermatology clinic.1 In 1660, Hafenreffer defined itch as an “unpleasant sensation that elicits the desire or reflex to scratch.”2 For a long time, the neural mechanisms underlying the transmission of itch remained elusive. In the last decade, the pathophysiology of itch has been intensively investigated and significant progress has been made in understanding its cellular and molecular mechanisms. Itch is classified as acute or chronic. According to the International Forum for the Study of Itch, acute pruritus is defined as an itch lasting less than 6 hours, while chronic pruritus is an itch persisting for 6 or more weeks.3,4 Chronic itch is a complex multifactorial phenomenon that may arise primarily from skin diseases, such as atopic dermatitis.
Pruritus is associated with a marked reduction in quality of life and has been reported to be as debilitating as chronic pain.1-5 If left untreated, pruritus can lead to skin damage through the self-perpetuating, counterproductive itch-scratch cycle, and to severe sleep impairment, mood disturbances, and poorer performance at work and/or school.9 Unfortunately, pruritus is particularly difficult to treat. To date, there are no target-specific treatments available for itch, and antipruritic therapies are only somewhat effective, since they do not always successfully address the underlying cause.1,9 Currently, the medications used to treat itch include antihistamines, opioid receptor agonists or antagonists, corticosteroids, and in severe cases, antidepressants. These agents provide some degree of itch relief; however, no complete resolution is attained in most cases.10 Corticosteroid therapy may be effective, but its use is limited due to its dose- and time-dependent side effects, including risk of adrenal axis suppression, skin atrophy, tachyphylaxis, striae, rosacea-like symptoms, peri-oral dermatitis, acne, and purpura.11-14 According to expert opinion, new substances and classes of antipruritic drugs are needed urgently.10

It has become increasingly clear that current antihistamines, which are of benefit in treating itch of allergic causes (such as immediate hypersensitivity reactions), are mostly ineffective in controlling the itch associated with diseases such as atopic eczema or psoriasis.15,16 This suggests that nonhistaminergic mechanisms are predominantly involved in pruritus. Current neurobiological models of itch transmission recognize the existence of distinct peripheral and central neural pathways that transduce histamine-based and nonhistamine-based forms of itch.15-19

One of the nonhistaminergic pathways that has been elucidated recently is the cowhage itch pathway.20 As postulated from the pioneering work of Shelley and Arthur almost 60 years ago,21 the cowhage plant releases a cysteine protease named mucunain, which binds to and activates protease-activated receptors PAR2 and PAR4.20 The PAR2–mediated itch pathway has been implicated in the pathophysiology of pruritus in atopic eczema.19,22 Therefore, cowhage itch has been proposed as a valuable experimental model for itch in humans.23-26

The cowhage itch model, using cowhage spicules, has been employed to study the efficacy of various topical antipruritic formulations.26-28 In a study performed in healthy subjects, as well as in patients with atopic dermatitis, we have demonstrated that, in comparison with the classical model using histamine, cowhage itch is a robust, reliable, and reproducible experimental model that is highly effective to induce an acute and transient itch.22 Typically, after the application of spicules, cowhage itch has an onset time of about 30–90 seconds, peaks after 90–120 seconds, and lasts for approximately 6–8 minutes. In a previous study, we utilized cowhage itch to compare the antipruritic efficacy of TriCalm® hydrogel with two other antipruritic topical agents: 2% diphenhydramine and 1% hydrocortisone.26

This study was conducted to test the antipruritic effect of the steroid-free topical hydrogel formulation, TriCalm hydrogel, in reducing itch intensity and duration, when itch was induced with cowhage spicules. TriCalm hydrogel is an over-the-counter (OTC) topical formulation designed to alleviate skin irritation (itching, burning, or stinging sensations). We compared the ability of this topical agent to relieve skin irritation (its antipruritic efficacy) with topical 2% diphenhydramine and 1% hydrocortisone, and with its own hydrogel vehicle.

Materials and methods
Study design and subjects
This study employed a double-blinded, vehicle-controlled, randomized, crossover design. Adult men and women between 18 and 50 years of age were included in this study if they were in general good health and had no disease that could impair evaluation of itch or pain perception (such as peripheral neuropathy). The exclusion criteria included current or recent use (within 1 week prior to study initiation) of oral or topical analgesics (such as antihistamines, opioids, and neuroleptics) or other medications known to interfere with itch or pain perception; use of emollients on the forearms on the day of the study, or use of medicated topical preparations on the forearms for the week prior to the study; history of neuropathy-causing diseases, such as uremia; history of uncontrolled thyroid disease; uncontrolled diabetes mellitus or diabetic neuropathy; and allergy to any of the study medications.

The study was performed in accordance with the current version of the Declaration of Helsinki (52nd WMA General Assembly, Edinburgh, Scotland, 2000). The trial was conducted in agreement with the International Conference on Harmonisation (ICH) guidelines on Good Clinical Practices (GCP). All subjects provided written informed consent to participate in the study.

Demographics and characteristics of study participants
Forty-eight subjects, including 20 men and 28 women between 19 and 50 years of age (mean ± standard deviation: 35.0±10.1
years) were tested. Of a total of 49 subjects screened, one participant did not fulfill study criteria. Subjects were free to withdraw from the study at any time without giving a reason; however, no subjects withdrew from the study. The results were analyzed in 47 healthy subjects, as one data set from one subject was not included in the analysis due to an exceedingly atypical, prolonged itch response (in excess of 40 minutes).

**Cowhage itch induction**

Itch was induced by the application of 40–45 cowhage spicules, which were counted under a magnifying lens and then were rubbed into the subject’s skin by a study investigator, as we described previously. The spicules were rubbed gently in a circular motion within a 16 cm² square area of skin, for 45 seconds. A sterile gauze perforated in a rectangular shape matching the 4x4 cm treatment area was used to cover the surrounding skin and prevent the spicules from stimulating the skin outside the designated area. At the conclusion of each experiment, when itch had subsided, the spicules were removed using adhesive tape (Scotch; 3M, St Paul, MN, USA).

**Antipruritic agents tested**

Treatments administered consisted of TriCalm hydrogel; hydrogel vehicle of TriCalm; 2% diphenhydramine; and Cortizone-10®, containing 1% hydrocortisone. TriCalm hydrogel is an OTC product manufactured by Cosmederm Bioscience, Inc. (San Diego, CA, USA) containing as the active ingredient aluminum acetate 0.2%. Cortizone-10 (Rite Aid, Camp Hill, PA, USA) was purchased as an OTC product from a local Rite Aid pharmacy. A lotion containing 2% diphenhydramine was compounded by La Vita Pharmacy (San Diego, CA, USA) to avoid the alcohols used in the formulation of a commercially available OTC Benadryl® (diphenhydramine), and other, flavored, ingredients such as menthol, that could affect the “blinding” process and may have interfered with the study’s outcome (since these ingredients are counterirritants that can have an effect on itch perception). A pretreatment design was used, ie, topical agents were applied to the skin and left in place for 15 minutes prior to itch induction in order to minimize differences in penetration rates and pharmacokinetics for the agents tested.

**Application of cowhage spicules and topical antipruritic agents**

Cowhage spicules and topical antipruritic agents were applied in the following sequence. First, itch was induced with cowhage as a control in the absence of any treatment, on the upper side of the volar aspect of the right forearm, on a 16 cm² (4x4 cm) square area. Then, randomized applications of topical 2% diphenhydramine, 1% hydrocortisone, TriCalm hydrogel, and hydrogel vehicle were performed on four other rectangular areas of the same size, two each on the right and left forearms. After 15 minutes of pretreatment with the test agents, the excess (unabsorbed) amount was removed using a paper towel. Cowhage spicules were subsequently applied in the same fashion as for the control, in four distinct experiments. The assignment of treatment on the four skin areas followed the crossover randomization scheme known as the Williams single, wherein the four sequences of applications were repeated in every four subjects in such a way that every test site received a topical agent just once, and the order of application was changed for the next participant, with a repetition period of 4. This design was selected to avoid order effects and a potential pairing selection bias of the same test area with the same agent. Each experiment using a different topical agent was separated from the subsequent one by a break of 20 minutes, counted from the moment when itch subsided in the previous step.

Cowhage itch was recorded for its full duration (in seconds) until it resolved completely. The starting point (t₀) for collection of ratings coincided with the moment when cowhage application was stopped. Using a numerical 10 cm visual analog scale (VAS), from 0 (no itch) to 10 (maximum unbearable itch), itch intensity was assessed every 15 seconds until itch sensation had completely subsided for all conditions. Spicules were left in place until experiments were concluded and itch ratings completely and stably returned to 0 (until three consecutive zeros were recorded). Area under the curve (AUC) was calculated from the temporal profile curves of itch ratings as a function of time.

**Statistical analysis**

All statistical analyses were performed using PASW® 18.0 software (SAS Institute Inc., Cary, NC, USA) with statistical significance threshold set at P<0.05. The peak VAS itch ratings, AUC, and the overall duration for each treatment arm and the cowhage itch control were compared using a mixed model and were post hoc corrected by the Bonferroni method.

**Results**

**Effect of treatments on peak itch intensity, itch duration, and total itch perceived (AUC)**

Data were obtained from the cowhage itch arm alone in the absence of any treatment (control) and with TriCalm.
hydrogel, topical 2% diphenhydramine, 1% hydrocortisone, and hydrogel vehicle on four other rectangular areas of the same size, two each on the right and left forearms. The cowhage itch model demonstrated highly reproducible characteristics, showing amplitude and temporal features very similar to those obtained in the double-blind, vehicle-controlled study we conducted previously in 32 healthy volunteers.26 Figure 1 shows the time-course curve of itch intensity. Among the three antipruritic agents tested, TriCalm hydrogel produced the highest reduction of itch, in all three parameters: intensity (VAS scale 0–10), itch duration (seconds), and total itch (AUC). AUC integrates the overall duration and instantaneous itch intensity at equally spaced sampling time points. Data for these endpoints are provided in Figure 2.

The antipruritic effect of treatments versus cowhage itch

Compared with the control cowhage itch, TriCalm effectively reduced peak itch intensity (± standard error of the mean [SEM]) by 2.72±0.42 VAS units, equivalent to a 41.3% reduction \((P<0.001)\); duration of itch (± SEM) by 163±33 seconds, equivalent to a 39.8% reduction \((P<0.001)\); and total itch perceived (AUC) by 50.5% \((P<0.001)\) (Figure 3). In contrast, 2% diphenhydramine reduced peak itch intensity by 1.16±0.42 VAS units, equivalent to a 17.6% reduction \((P=0.057, \text{not significant [ns]})\); did not reduce the duration of itch, which was in fact prolonged on average by 24.9 seconds; and reduced total itch perceived (AUC) by 8.6% (ns) (Figure 3). The 1% hydrocortisone reduced peak itch intensity by 0.36±0.42 VAS units, equivalent to a 5.5% reduction (ns); duration of itch by 50.2±33 seconds, equivalent to a 12.3% reduction (ns); and total itch perceived (AUC) by 6.2% (ns) (Figure 3).

![Figure 1](https://www.dovepress.com/)

**Figure 1** Time course of itch intensity for all conditions investigated (VAS ratings 0–10).

**Note:** VAS is a numerical 10 cm VAS from 0 (no itch) to 10 (maximum unbearable itch).

**Abbreviation:** VAS, visual analog scale.

![Figure 2](https://www.dovepress.com/)

**Figure 2** Effect of treatments on (A) peak itch intensity (VAS units), (B) itch duration (seconds), and (C) total itch perceived (AUC).

**Note:** *Decrease in itch intensity, duration, and AUC was significant in comparison to the control cowhage itch. Results were considered statistically significant for \(P<0.05\).

**Abbreviations:** AUC, area under the curve; SEM, standard error of the mean; VAS, visual analog scale.
TriCalm hydrogel performance versus its own hydrogel vehicle (vehicle control)
In the vehicle control group, the peak itch intensity (± SEM) was 5.54±0.39 VAS units, itch duration was 368±22.7 seconds, and total itch perceived (AUC) was 1,134±132 units. TriCalm hydrogel significantly reduced peak itch intensity when compared to its own hydrogel vehicle by 1.67±0.42 VAS units, equivalent to a 30.1% reduction (P<0.001); reduced duration of itch (± SEM) by 122±33 seconds, equivalent to a 33% reduction (P<0.001); and reduced total itch perceived (AUC) by 40% (P<0.02).

Comparative efficacy of TriCalm versus 2% diphenhydramine and 1% hydrocortisone
TriCalm hydrogel was significantly superior to all the other treatments, 2% diphenhydramine and 1% hydrocortisone, in reduction of peak itch intensity (P<0.002 versus diphenhydramine; P<0.001 versus hydrocortisone), itch duration (P<0.008 versus hydrocortisone [note: diphenhydramine did not reduce itch duration]), and total itch perceived (AUC, P<0.001 for TriCalm hydrogel versus each comparator).

Comparing the therapeutic effects in reduction of AUC in comparison to the control itch curve, TriCalm hydrogel was almost six times more effective than 2% diphenhydramine in antipruritic action and over eight times more effective than 1% hydrocortisone, both commonly used as OTC topical antipruritic agents (Table 1).

Discussion
There is an unmet need for an efficacious targeted treatment of pruritus. Data from randomized, controlled trials of antipruritic agents used for treatment of itch are limited, and treatments currently used in clinical practice have variable and, in most cases, suboptimal effectiveness.5 Currently available antihistamines, which are commonly used as first-line therapy, are not effective in reducing itch in various acute or chronic systemic conditions.29 This may be because histamine is not the principal mediator of itch in the majority of conditions characterized by persistent itch.22 In fact, proteases such as cathepsin S, mast cell tryptase, and kallikrein, which act on the PAR2 receptor, may play an important role in the pathophysiology of itch; therefore, an exogenous PAR2 ligand, such as the mucunain released by cowhage spicules, represents a relevant itch stimulus and model for studying

**Figure 3** Reduction of (A) peak itch intensity (VAS units), (B) itch duration (seconds), and (C) total itch perceived (AUC) versus control.
Notes: *P<0.001; diphenhydramine did not reduce cowhage itch duration. Results were considered statistically significant for P<0.05.
Abbreviations: AUC, area under the curve; SEM, standard error of the mean; VAS, visual analog scale.
Table 1 Therapeutic efficacy of TriCalm hydrogel in reducing peak itch intensity, itch duration, and overall itch (AUC) in comparison with the other two agents analyzed, in reference to the control itch curve (n=47)*

<table>
<thead>
<tr>
<th>Endpoint ratio</th>
<th>TriCalm vs 2% diphenhydramine</th>
<th>TriCalm vs 1% hydrocortisone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduction of peak itch intensity (VAS units)</td>
<td><strong>P&lt;0.002</strong></td>
<td><strong>P=0.001</strong></td>
</tr>
<tr>
<td>Reduction of itch duration (seconds)</td>
<td><strong>P&lt;0.008</strong></td>
<td><strong>P&lt;0.008</strong></td>
</tr>
<tr>
<td>Reduction of total itch perceived (AUC)</td>
<td><strong>P&lt;0.001</strong></td>
<td><strong>P&lt;0.001</strong></td>
</tr>
</tbody>
</table>

**Notes:** *The effect of each agent was calculated versus the same control curve.
A ratio of the effect produced by TriCalm/the effect induced by the other two antipruritics was calculated; *diphenhydramine did not reduce cowhage itch duration.
Results were considered statistically significant for **P<0.05**.

**Abbreviations:** AUC, area under the curve; N/A, not applicable; VAS, visual analog scale.

TriCalm hydrogel is superior to topically applied antipruritics in reducing peak itch intensity, itch duration, and overall itch (AUC). In this study, the results were considered statistically significant for **P<0.05**. The endpoint ratios show a clear advantage for TriCalm hydrogel over the control curve.

The therapeutic efficacy of TriCalm hydrogel is demonstrated in reducing itch, with a significant reduction in peak itch intensity (2.72/1.16–2.34), itch duration (163/50.2–3.24), and overall itch (700/19.2–5.87) compared to the control group. These findings are consistent with previous studies that have highlighted the effectiveness of TriCalm hydrogel in treating pruritic conditions.

**References**